Suplatast tosilate (IPD®), a new immunoregulator, is effective in vitiligo treatment

Journal of Dermatology

Volumn 25, Issue 4, 1998, Pages 250-255

  Nihei, Yoshimichi ^a   Nishibu, Akiko ^a   Kaneko, Fumio ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Autoantibody; IL 4; Suplatast tosilate; Vitiligo

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 4; MICROSOME ANTIBODY; SUPLATAST TOSYLATE; THYROID ANTIBODY;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HELPER CELL; HUMAN; IMMUNOREGULATION; MALE; ORAL DRUG ADMINISTRATION; SKIN PIGMENTATION; VITILIGO;

EID: 0031956639     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1998.tb02391.x     Document Type: Article

References (49)

1. Koga M: Vitiligo: A new classification and therapy, Br J Dermatol, 97: 255-261, 1977.
2. Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI: Auoimmune vitiligo: Detection of antibodies to melanin-producing cells, New Eng J Med, 297: 634-637, 1977.
3. Bystryn JC: Immune mechanisms in vitiligo, Immunol Series, 46: 447-473, 1989.
4. Naughton GK, Eisinger M, Bystryn JC: Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation, J Invest Dermatol, 81: 540-542, 1983.
5. Norris DA, Kissinger RM, Naughton GM, Bystryn JC: Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity, J Invest Dermatol, 90: 783-789, 1988.
6. Gilhar A, Zelickson B, Ulman Y, Etzioni A: In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo, J Invest Dermatol, 105:683-686, 1995.
7. Hann SK, Kim HI, Im S, Park YK, Gui J, Bystryn JC: The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients, J Dermatol Sci, 63: 201-205, 1993.
8. Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoier-Madsen M: High frequency of thyroid dysfunction in patients with vitiligo, Acta Dem Venereol, 74: 120-123, 1994.
9. Park YK, Kim NS, Hann SK, Im S: Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients, J Dermatol Sci, 11: 111-120, 1996.
10. Cui J, Arita Y, Bystryn JC: Characterization of vitiligo antigens, Pigment Cell Res, 8: 53-59, 1995.
11. Austin LM, Boissy RE: Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo, Am J Pathol, 146: 1529-1541, 1995.
12. Baharav E, Merimski O, Shoenfeld Y, et al: Tyrosinase as an autoantigen in patients with vitiligo, Clin Exp Immunol, 105: 84-88, 1996.
13. Asthana D, Fujii Y, Huston GE, Lindstrom J: Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors, Clin Immunol Immunopathol, 67: 240-248, 1993.
14. Ramanathan S, de Kozak Y, Saoudi A, et al: Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats, J Immunol, 157: 2209-2215, 1996.
15. Klinman DM: IgG1 and IgG2 production by autoimmune B cells treated in vitro with IL-4 and IFN-gamma, J Immunol, 144:2529-2534, 1990.
16. Nakajima A, Hirose S, Yagita H, Okumura K: Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice, J Immunol, 158: 1466-1472, 1997.
17. Mignon-Godefroy K, Brazillet MP, Rott O, Charreire J: Distinctive modulation by IL-4 and IL-10 of the effector function of murine thyroglobulin-primed cells in "transfer-experimental autoimmune thyroiditis", Cellular Immunol, 162: 171-177, 1995.
18. Yanagihara Y, Kiniwa M, Ikizawa K, Shida T, Matsuura N, Kocla A: Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2) Regulation of human IgE response, Jap J Pharmacol, 61: 31-39, 1993.
19. Matsuura N, Mori H, Nagai H, Koda A: Effects of suplatast tosilate (IPD-1151T) on antibody formations in mice, Nippon Yakurigaku Zasshi, 100: 485-493, 1992. (in Japanese)
20. Yanagihara Y, Kiniwa M, Ikizawa K, et al: Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (1) Regulation of murine IgE response, Jap J Pharmacol, 61: 23-30, 1993.
21. Matsuura N, Mori H, Nagai H, Koda A: Effect of suplatast tosilate (IPD-1151T) on types I-IV allergic reactions, Nippon Yakurigaku Zasshi, 100: 495-501, 1992. (in Japanese)
22. Konno S, Asano K, Gonokami Y, Kurokawa M, Kawazu K, Adachi M: Effect of IPD-1151T (Suplatast Tosilate) on airway hyperresponsiveness in mice, Arerugi, 44: 556-561, 1995.
23. Konno S, Adachi M, Asano K, et al: Suppressive effects of IPD-1151T (suplatast-tosilate) on induction of mast cells from normal mouse splenocytes, Eur J Pharmacol, 259: 15-20, 1994.
24. Yamaya H, Basaki Y, Togawa M, Kojima M, Kiniwa M, Matsuura N: Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents, Life Sciences, 56: 1647-1654, 1995.
25. Drake LA, Dinehart SM, Farmer ER, et al: Guidelines of care for vitiligo, J Am Acad Dermatol, 35: 620-626, 1996.
26. Todes-Taylor N, Abel EA, Cox AJ: The occurrence of vitiligo after psoralens and ultraviolet A therapy, J Am Acad Dermatol, 9: 526-532, 1983.
27. Hirata F, Toyoshima S, Axelrod J, Waxdal MJ: Phospholipid methylation: A biochemical signal modulating lymphocyte mitogenesis, Proc Natl Acad Sci USA, 77: 862-865, 1980.
28. Riddik DH, Gallo RC: The transfer RNA methylases of human lymphocytes (I): Induction by PHA in normal lymphocytes, Blood, 37: 282-292, 1971.
29. Renoux G, Renous M: Immunostimulant effect of an imidothizole in the immunization of mice infected with Brucella abortsu, CR Acad Sci Paris 272D: 349-350, 1971.
30. Schumacher K, Maerker-Alzer G, Schaaf W: Influence of D-penicillamine on the immune response of mice, Arzeim-Forsch, 25: 600-606, 1975.
31. Yamamoto I, Ohmori H, Okimura T: An immunopharmacological profile in vitro. Jap J Inflammat, 1: 133-138, 1980.
32. Walz DT, Griswold DE: Immunopharmacology of gold sodium thiomalate and auranofin (SK & FD-39162): Effects on cell-mediaged immunity, Inflammation, 3: 117-127, 1978.
33. Pasricha JS, Khaitan BK: Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease, Internat'l J Dermatol, 32: 753-757, 1993.
34. Geraldez CB, Gutierrez GT: A clinical trial of clobetasol propionate in Filipino vitiligo patients, Clinical Therap, 9: 474-482, 1987.
35. Pasricha JS, Khera V: Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease, Intern'l J Dermatol, 33: 584-587, 1994
36. Gokhale BB, Parakh AP: Cyclophosphamide in vitiligo, Indian J Dermatol, 28: 7-10, 1983.
37. Oakley AM: Rapid repigmentation after depigmentation therapy: Vitiligo treated with monobenzyl ether of hydroquinone, Australasian J Dermatol, 37: 96-98, 1996.
38. Suite M, Quamina DB: Treatment of vitiligo with topical melagenine - A human placental extract, J Am Acad Dermatol, 24: 1018-1019, 1991.
39. Nordlund JJ, Halder R: Melagenina. An analysis of published and other available data, Dermatologica, 181: 1-4, 1990.
40. Muto M, Furumoto H, Ohmura A, Asagami C: Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture, J Dermatol, 22: 770-772, 1995.
41. Schallreuter KU, Wood JM, Lemke KR, Levenig C: Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: A case study on 33 patients, Dermatology, 190: 223-229, 1995.
42. Siddiqui AH, Stolk LM, Bhaggoe R, Hu R, Schutgens RB, Westerhof W: L-phenylal anine and UVA irradiation in the treatment of vitiligo, Dermatology, 188: 215-218, 1994.
43. Morliere P, Honigsmann H, Averbeck D, et al: Phototherapeutic, photobiologic, and photosensitizing properties of khellin, J invest Dermatol, 90: 720-724, 1988.
44. Ortel B, Tanew A, Honigsmann H: Treatment of vitiligo with khellin and ultraviolet A, J Am Acad Dermatol, 18:693-701, 1988.
45. Srinivas CR, Shenoi SD, Balachandran C: Acceleration of repigmentation in vitiligo by topical minoxidil in patients on photochemotherapy, Intern'l J Dermatol, 29: 154-155, 1990.
46. Tsuji T, Hamada T: Topically administered fluorouracil in vitiligo, Arch Dermatol, 119: 722-727, 1983.
47. Goolamali SK: Levodopa in vitiligo, Lancet, 1: 675-676, 1973.
48. Kahn AM, Cohen MJ: Vitiligo: Treatment by dermabrasion and epithelial sheet grafting, J Am Acad Dermatol, 33: 646-648, 1995.
49. Olsson MJ, Juhlin L: Transplantation of melanocytes in vitiligo, Br J Dermatol, 132: 587-591, 1995.